Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
- PMID: 26231040
- PMCID: PMC4521140
- DOI: 10.7554/eLife.07420
Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
Abstract
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered report describes the proposed replication plan of key experiments from 'Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases' by Xu and colleagues, published in Cancer Cell in 2011 (Xu et al., 2011). The key experiments being replicated include Supplemental Figure 3I, which demonstrates that transfection with mutant forms of IDH1 increases levels of 2-hydroxyglutarate (2-HG), Figures 3A and 8A, which demonstrate changes in histone methylation after treatment with 2-HG, and Figures 3D and 7B, which show that mutant IDH1 can effect the same changes as treatment with excess 2-HG. The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.
Keywords: 2-hydroxyglutarate; IDH; Reproducibility Project: Cancer Biology; biochemistry; human; human biology; medicine; methodology.
Conflict of interest statement
RP:CB: We disclose that EI, FT, and JL are employed by and hold shares in Science Exchange Inc. The experiments presented in this manuscript will be conducted by BE at the Proteomics and Mass Spectrometry Facility, which is a Science Exchange lab.
The other authors declare that no competing interests exist.
Similar articles
-
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Elife. 2016 Feb 26;5:e12626. doi: 10.7554/eLife.12626. Elife. 2016. PMID: 26943899 Free PMC article.
-
Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation.Elife. 2016 Mar 11;5:e10860. doi: 10.7554/eLife.10860. Elife. 2016. PMID: 26971564 Free PMC article.
-
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.Cancer Cell. 2011 Jan 18;19(1):17-30. doi: 10.1016/j.ccr.2010.12.014. Cancer Cell. 2011. PMID: 21251613 Free PMC article.
-
D-2-Hydroxyglutarate in Glioma Biology.Cells. 2021 Sep 7;10(9):2345. doi: 10.3390/cells10092345. Cells. 2021. PMID: 34571995 Free PMC article. Review.
-
Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.Chem Res Toxicol. 2022 Feb 21;35(2):115-124. doi: 10.1021/acs.chemrestox.1c00254. Epub 2022 Jan 12. Chem Res Toxicol. 2022. PMID: 35018778 Review.
Cited by
-
Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer.Front Oncol. 2021 Apr 26;11:644857. doi: 10.3389/fonc.2021.644857. eCollection 2021. Front Oncol. 2021. PMID: 33981605 Free PMC article. Review.
-
Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.Elife. 2021 Dec 7;10:e73430. doi: 10.7554/eLife.73430. Elife. 2021. PMID: 34874009 Free PMC article.
-
5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients.J Cell Mol Med. 2019 May;23(5):3530-3537. doi: 10.1111/jcmm.14252. Epub 2019 Mar 26. J Cell Mol Med. 2019. PMID: 30912288 Free PMC article.
-
Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer.Mol Cancer Res. 2020 Dec;18(12):1803-1814. doi: 10.1158/1541-7786.MCR-20-0359. Epub 2020 Sep 10. Mol Cancer Res. 2020. PMID: 32913111 Free PMC article.
-
Challenges for assessing replicability in preclinical cancer biology.Elife. 2021 Dec 7;10:e67995. doi: 10.7554/eLife.67995. Elife. 2021. PMID: 34874008 Free PMC article.
References
-
- Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes & Development. 2014;28:479–490. doi: 10.1101/gad.231233.113. - DOI - PMC - PubMed
-
- Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJM, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567. doi: 10.1016/j.ccr.2010.11.015. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
